Market Place
Sourcing Support
Addressing Nitrosamine Risks in Pharmaceutical Manufacturing
10 Oct 2024 //
PRESS RELEASE
Alkem Lab`s Generics Ticagrelor Receives Tentative Approval in US
12 Sep 2024 //
FDA
Changzhou`s Generic Ticagrelor Receives Approval in the U.S.
07 Jun 2023 //
FDA
Annora`s Generic Ticagrelor Receives Approval in the U.S.
02 Jun 2023 //
FDA
Changzhou`s Generic Ticagrelor Receives Approval in the U.S.
12 Dec 2022 //
FDA
PhaseBio shows Brilinta reversal agent can work in an emergency
16 Nov 2021 //
BIOSPACE
PhaseBio`s Brilinta reversal agent wins midstage test
03 Nov 2021 //
FIERCEBIOTECH
Sobi drug cuts death risk; heart drugs may help prevent COVID-19 blood clots
10 Sep 2021 //
REUTERS
PhaseBio Announces European Licensing Agreement with Alfasigma S.p.A
16 Jun 2021 //
BUSINESSWIRE
PhaseBio taps a manufacturing partner for Brilinta-reversing med
11 Mar 2021 //
FIERCEBIOTECH
Ticagrelor Nonsuperior to Clopidogrel for Prevention of MI After Elective
17 Nov 2020 //
FIRSTWORDPHARMA
Ticagrelor was not superior to clopidogrel to reduce heart attack risk
16 Nov 2020 //
HEART
AstraZeneca`s Brilinta combo reduces rate of disabling stroke
09 Nov 2020 //
PHARMAFILE
BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients
06 Nov 2020 //
BUSINESSWIRE
AstraZeneca`s Brilinta wins FDA nod for stroke patients
06 Nov 2020 //
FIERCE PHARMA
Brilinta approved in the US to reduce the risk of stroke in patients
05 Nov 2020 //
PRESS RELEASE
PhaseBio Doses First Patients as Part of the REVERSE-IT Trial of Bentracimab
06 Oct 2020 //
BUSINESSWIRE
AstraZeneca puts COVID-19 spin on heart disease awareness, Brilinta campaigns
08 Sep 2020 //
FIERCE PHARMA
AZ’s Brilinta reduces the rate of stroke and death in patients
16 Jul 2020 //
PHARMFILE
BRILINTA Significantly Reduced the Rate of the Composite of Stroke and Death
16 Jul 2020 //
BUSINESSWIRE
AZ unveils detailed data from THALES trial
15 Jul 2020 //
PHARMATIMLES
US priority review for AZ` Brilinta/aspirin combination
09 Jul 2020 //
PHARMATIMES
Brilinta granted FDA Priority Review for the reduction of subsequent stroke
09 Jul 2020 //
PRESS RELEASE
BRILINTA Approved in the US to Reduce the Risk of First Heart Attack or Stroke
01 Jun 2020 //
BUSINESSWIRE
AstraZeneca`s Heart Drug Gets FDA Nod
30 May 2020 //
NYTIMES
Development Update: U.S. FDA Grants Breakthrough Designation to CytoSorb
20 Apr 2020 //
YAHOO
Hec Pharm`s Generic Ticagrelor Receives Approval in US
07 Apr 2020 //
FDA
Sigmapharm Labs LLC Generic Ticagrelor Receives Approval In The US
07 Apr 2020 //
FDA
Brilinta found to reduce bleeding vs dual therapy
31 Mar 2020 //
PHARMA TIMES
AZ`s Brilinta solo topped aspirin combo in patient bleeding
30 Mar 2020 //
FIERCE PHARMA
BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients
30 Mar 2020 //
BUSINESSWIRE
After NASH flops, Conatus becomes Histogen via reverse merger
30 Jan 2020 //
FIERCE BIOTECH
AZ has dumped billions into Brilinta, but will it ever pay off?
30 Jan 2020 //
FIERCE PHARMA
Brilinta hits endpoint in late-stage stroke trial
28 Jan 2020 //
PHARMA TIMES
AstraZeneca makes case for use of blood thinner Brilinta in stroke patients
28 Jan 2020 //
ENDPTS
AstraZeneca`s Brilinta tops aspirin in reducing stroke risks
27 Jan 2020 //
FIERCE PHARMA
BRILINTA Met Primary Endpoint in the Phase III THALES Trial in Stroke
27 Jan 2020 //
BUSINESSWIRE
Brilinta reduces CV events but increases bleeding
03 Sep 2019 //
PHARMA TIMES
AZ’s clot-fighter Brilinta shows promise in diabetics with heart disease
26 Feb 2019 //
ENDPTS
AstraZeneca strikes ‘novel’ deal with Medicare plan to lower out-of-pocket costs
28 Jan 2019 //
STAT NEWS
Hisun Pharm Hangzhou`s Generic Ticagrelor Receives Approval in US
23 Jan 2019 //
FDA
Amneal Pharm`s Generic Ticagrelor Receives Approval in US
23 Jan 2019 //
FDA
Idorsia`s selatogrel hits goals in phase 2 cardiovascular trials
18 Dec 2018 //
FIERCE BIOTECH
Alkem Labs`s Generic Ticagrelor Receives Tentative Approval in US
13 Nov 2018 //
FDA
Prinston Pharma`s Generic Ticagrelor Receives Approval in US
08 Nov 2018 //
FDA
Hisun Pharm Hangzhou`s Generic Ticagrelor Receives Tentative Approval in US
19 Oct 2018 //
FDA
PhaseBio Announces Pricing of Initial Public Offering
17 Oct 2018 //
BIOSPACE
Watson Labs` Generic Ticagrelor Receives Approval in US
05 Sep 2018 //
FDA
Brilinta (ticagrelor) : AstraZeneca UK et al v. Hisun Pharmaceutical
18 Aug 2018 //
PATENT LITIGATION
AstraZeneca-DRL patent case: Fate of Rs 2.35 bn drug to be decided today
31 Jul 2018 //
BUSINESS STANDARD
Hidden conflicts? Pharma Exec advising the U.S. govt on drug approvals
07 Jul 2018 //
SCIENCEMAG
AZ chief Pascal Soriot says Crestor freefall could slow in H2
18 May 2018 //
FIERCE PHARMA
AZ enrolls first patient in Brilinta stroke trial
25 Jan 2018 //
PHARMA TIMES
Sandoz`s Generic Ticagrelor Receives Tentative Approval In US
25 Jan 2018 //
FDA
Amneal Pharm’s Generic Ticagrelor Receives Approval In US
21 Nov 2017 //
FDA
AZ books 3 percent sales drop for Q3
09 Nov 2017 //
PHARMA TIMES
AstraZen says extended treatment with Brilinta reduces risk of CV death by 29%
25 Aug 2017 //
PHARMABIZ
ESC: AstraZeneca`s Brilinta looks for a boost from long-term study
25 Aug 2017 //
FIERCE PHARMA
Enforcement Report - Week of July 19, 2017
19 Jul 2017 //
FDA
